M. E. Layton

956 citations

20 papers · 647 indexed · h-index 11

Co-authors: Matthew D. Shair Chuo Chen Craig W. Lindsley Michael J. Kelly Scott M. Sheehan Mark T. Bilodeau Stanley F. Barnett Sarah L. Huszar
Topics: Ion channel regulation and function (5 papers)Microbial Natural Products and Biosynthesis (4 papers)Neuroscience and Neuropharmacology Research (4 papers)
Cited by: Organic Chemistry Biotechnology Process Chemistry and Technology
Journals: Proceedings of the National Academy of Sciences Journal of the American Chemical Society Biological Psychiatry
Partner nations: United States United Kingdom China

In The Last Decade

M. E. Layton

20 papers receiving 639 citations

Peers

Countries citing papers authored by M. E. Layton

Since Specialization

Citations

This map shows the geographic impact of M. E. Layton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. E. Layton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. E. Layton more than expected).

Fields of papers citing papers by M. E. Layton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. E. Layton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. E. Layton. The network helps show where M. E. Layton may publish in the future.

Co-authorship network of co-authors of M. E. Layton

This figure shows the co-authorship network connecting the top 25 collaborators of M. E. Layton. A scholar is included among the top collaborators of M. E. Layton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. E. Layton. M. E. Layton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia 2024 ·Journal of Pharmacology and Experimental Therapeutics ·Sean M. Smith,Dawn Toolan,Monika Kandebo,Joshua D. Vardigan,Izzat T. Raheem,M. E. Layton,Jeffrey C. Kern,Christopher D. Cox,Liza Gantert,Kerry Riffel,Eric D. Hostetler,Jason M. Uslaner	1
2	Analgesia and peripheral c-fiber modulation by selective Nav1.8 inhibition in rhesus 2024 ·Pain ·Joshua D. Vardigan,(unknown),(unknown),Chien-Jung Huang,Michelle K. Clements,Yuxing Li,Richard L. Kraus,Michael J. Breslin,Christopher J. Bungard,(unknown),(unknown),(unknown),M. E. Layton,Shawn J. Stachel,Henry S. Lange,Alan T. Savitz,Vincent P. Santarelli,Darrell A. Henze,Jason M. Uslaner	3
3	Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia 2023 ·Journal of Medicinal Chemistry ·M. E. Layton,Jeffrey C. Kern,(unknown),William D. Shipe,Izzat T. Raheem,Monika Kandebo,Robert P. Hayes,Sarah L. Huszar,Donnie Eddins,Bennett Ma,(unknown),Gordon K. Wollenberg,Jing Li,(unknown),Georgia B. McGaughey,Jason M. Uslaner,Sean M. Smith,Paul J. Coleman,Christopher D. Cox	22
4	P546. Preclinical Characterization and Phase 1 Evaluation of the Tolerability, Pharmacokinetics, and Enzyme Occupancy of MK-8189, a Novel PDE10A Inhibitor 2022 ·Biological Psychiatry ·Sean M. Smith,Jason M. Uslaner,Monika Kandebo,Eric D. Hostetler,Izzat T. Raheem,M. E. Layton,Liza Gantert,Kerry Riffel,Christopher D. Cox,Sauzanne Khalilieh,Inge De Lepeleire,Guy Bormans,Marleen Depré,Jan de Hoon,Koen Van Laere	1
5	Discovery of Arylsulfonamide Na _v 1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile 2021 ·ACS Medicinal Chemistry Letters ·Anthony J. Roecker,M. E. Layton,(unknown),Michael J. Kelly,Thomas J. Greshock,Richard L. Kraus,Yuxing Li,Rebecca M. Klein,Michelle K. Clements,Christopher J. A. Daley,Aneta Jovanovska,Jeanine Ballard,Deping Wang,Fuqiang Zhao,Andrew P. J. Brunskill,Xuanjia Peng,Xiu Wang,Haiyan Sun,Andrea K. Houghton,Christopher S. Burgey	8
6	Na _v 1.7 target modulation and efficacy can be measured in nonhuman primate assays 2021 ·Science Translational Medicine ·Richard L. Kraus,Fuqiang Zhao,(unknown),Dan Zhou,Joshua D. Vardigan,Andrew Danziger,Yuxing Li,Christopher J. A. Daley,Jeanine Ballard,Michelle K. Clements,Rebecca M. Klein,Marie A. Holahan,Thomas J. Greshock,Ronald M. Kim,M. E. Layton,Christopher S. Burgey,Jordi Serra,Darrell A. Henze,Andrea K. Houghton	15
7	ATN/IPS security approach: Two-way mutual authentication, data integrity and privacy 2018 ·(unknown),(unknown),(unknown),M. E. Layton,Mark Stevenson	4
8	Kinetic Analysis of Membrane Potential Dye Response to NaV1.7 Channel Activation Identifies Antagonists with Pharmacological Selectivity against NaV1.5 2016 ·SLAS DISCOVERY ·Michael Finley,(unknown),(unknown),(unknown),Kelli Solly,(unknown),Michelle K. Clements,Antonella Converso,Sean P. Cook,(unknown),Richard L. Kraus,Ming‐Tain Lai,M. E. Layton,Wei Lemaire,(unknown),Jixin Wang	5
9	Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis 2016 ·Bioorganic & Medicinal Chemistry Letters ·M. E. Layton,(unknown),(unknown),(unknown),Vadim Dudkin,(unknown),(unknown),Michael J. Kelly,R. M. Garbaccio,Julie A. O’Brien,Brian C. Magliaro,Jason M. Uslaner,Sarah L. Huszar,Kerry L. Fillgrove,Cuyue Tang,Yuhsin Kuo,Marlene A. Jacobson	7
10	Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI 2016 ·ACS Medicinal Chemistry Letters ·(unknown),Michael Rossi,Michael J. Kelly,(unknown),M. E. Layton,R. M. Garbaccio,Julie A. O’Brien,Brian C. Magliaro,Jason M. Uslaner,Sarah L. Huszar,Kerry L. Fillgrove,Cuyue Tang,Yuhsin Kuo,Leo A. Joyce,Edward C. Sherer,Marlene A. Jacobson	8
11	3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts 2010 ·Bioorganic & Medicinal Chemistry Letters ·Edward J. Brnardic,Mark E. Fraley,R. M. Garbaccio,M. E. Layton,John M. Sanders,Chris Culberson,Marlene A. Jacobson,Brian C. Magliaro,Pete H. Hutson,Julie A. O’Brien,Sarah L. Huszar,Jason M. Uslaner,Kerry L. Fillgrove,Cuyue Tang,Yuhsin Kuo,(unknown),George D. Hartman	30
12	The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors 2008 ·Current Cancer Drug Targets ·Craig W. Lindsley,Stanley F. Barnett,M. E. Layton,Mark T. Bilodeau	72
13	Recent Advances in the Development of NR2B Subtype-Selective NMDA Receptor Antagonists 2006 ·Current Topics in Medicinal Chemistry ·M. E. Layton,Michael J. Kelly,(unknown)	52
14	Subtype-Selective Noncompetitive Modulators of Metabotropic Glutamate Receptor Subtype 1 (mGluR1) 2005 ·Current Topics in Medicinal Chemistry ·M. E. Layton	12
15	1,2,4‐Triazines 2005 ·ChemInform ·Craig W. Lindsley,M. E. Layton	1
16	Synthesis of (-)-longithorone A: Using organic synthesis to probe a proposed biosynthesis 2004 ·Proceedings of the National Academy of Sciences ·(unknown),M. E. Layton,Matthew D. Shair	36
17	Biomimetic Synthesis of (−)-Longithorone A 2002 ·Journal of the American Chemical Society ·M. E. Layton,(unknown),Matthew D. Shair	177
18	Synthesis of (+)-CP-263,114 2000 ·Journal of the American Chemical Society ·Chuo Chen,M. E. Layton,Scott M. Sheehan,Matthew D. Shair	74
19	Synthesis of Cyclooctenones Using Intramolecular Hydroacylation 2000 ·Journal of the American Chemical Society ·(unknown),M. E. Layton,Matthew D. Shair	82
20	Stereospecific Synthesis of the CP-263,114 Core Structure 1998 ·Journal of the American Chemical Society ·Chuo Chen,M. E. Layton,Matthew D. Shair	37

About M. E. Layton

M. E. Layton is a scholar working on Pharmacology, Biological Psychiatry and Organic Chemistry, having authored 20 papers that have together received 647 indexed citations. Recurring topics across this work include Ion channel regulation and function (5 papers), Microbial Natural Products and Biosynthesis (4 papers) and Neuroscience and Neuropharmacology Research (4 papers). The work is most often cited by research in Organic Chemistry (428 citations), Biotechnology (57 citations) and Process Chemistry and Technology (17 citations). M. E. Layton has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Matthew D. Shair, Chuo Chen, Craig W. Lindsley, Michael J. Kelly, Scott M. Sheehan, Mark T. Bilodeau, Stanley F. Barnett, Sarah L. Huszar, Jason M. Uslaner and R. M. Garbaccio. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Biological Psychiatry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact